The expected amount of annual claims of Erbitux is KRW 48 billion while the one of Revlimid is KRW 32 billion

It is known that the expected amounts of claims for the 4 anticancer drugs registered through the Risk Share Agreementare worth of KRW 90 billion.

Although they are anticancer drugs for a rare disease that has a small number of patients, since they are extremely pricey, it is expected that they will become products that receive 10 billion won benefits. The gap of the claim amounts also vary be...